실적분석 2026년 7월 30일

Stryker ($SYK) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Beat Expectations, Shares Plunge After-Hours Despite Narrowed Outlook

Earnings Scorecard

Revenue: $6.589 billion (+9.4% year-over-year, vs. $6.579 billion expected) ✅ Beat

EPS (Earnings Per Share): Adjusted basis $3.69 (vs. $3.49 expected) ✅ Beat

Guidance: Maintained (narrowed range) — Full-year organic revenue growth 8.3%–9.3%, adjusted EPS $14.95–$15.10

Stock Reaction: After-hours -8.34% ($319) — As of 07:59 KST, 07-31

The Positives

Adjusted EPS beat expectations: Adjusted EPS of $3.69 comfortably exceeded the $3.49 consensus estimate.

Strong organic revenue growth: Organic revenue rose 9.0%, with both segments delivering balanced growth.

Margin expansion: Adjusted operating margin widened by 1.7 percentage points year-over-year to 27.4%.

Q2 revenue came in at $6.589 billion, up 9.4% year-over-year, and grew 9.0% on an organic basis excluding FX and acquisition impacts. While this only modestly topped the $6.579 billion consensus, the growth rate itself ranks among the more solid performances among large-cap medical device names. Adjusted EPS of $3.69 climbed 17.9% year-over-year and clearly outpaced the pre-announcement consensus of $3.49. For reference, GAAP EPS was $3.30, which includes one-off items and is best not directly compared to consensus.

By segment, Surgical & Neurotechnology revenue reached $3.6 billion (+9.7%), while Orthopaedics posted $3.0 billion (+9.1%) — both delivering strong results. Core product franchises such as Medical, Endoscopy, Trauma & Extremities led growth at close to double-digit levels, and the 1.7 percentage-point expansion in adjusted operating margin signals that both volume recovery and cost discipline were firing simultaneously. Management noted that recovery following the cyberattack first disclosed in March has progressed.

The Negatives

Capped full-year guidance upside: The company lowered the top end of its revenue growth outlook, leaving investors wanting more given the strong Q2 print.

Underperforming Vascular business: The Vascular segment posted a 0.7% year-over-year revenue decline.

Slower Hip growth: Hip revenue grew just 2.9%, highlighting a notable temperature gap within Orthopaedics.

The company described its 2026 full-year outlook as "narrowed." Organic revenue growth is guided at 8.3%–9.3%, with adjusted EPS of $14.95–$15.10. Compared with the prior range (issued at the time of Q1), the bottom end moved up slightly, but the top end of revenue growth was cut from 9.5% to 9.3%, while the top end of EPS was held flat at $15.10. Given how decisively Q2 results beat expectations, the market had likely been positioned for an upgrade and was disappointed to instead get a narrowing.

The picture was also mixed at the business-unit level. The Vascular segment stumbled, with US revenue down 6.7% driving a 0.7% overall decline, and Hip growth lagged at just 2.9%, trailing Knees, Trauma & Extremities. Additionally, the press release's risk factors still reference the cyberattack first reported on March 11, meaning the recovery narrative has not fully erased the lingering uncertainty.

What Management Said

CEO Kevin Lobo characterized the recovery following the cyberattack as meaningfully progressed and noted that Q2 delivered strong results across revenue, EPS, and operating cash flow. He emphasized the team's resilience, consistent innovation, and disciplined execution, explaining that Stryker is entering the second half of 2026 with momentum restored. He also expressed confidence in the company's ability to grow among the top tier of the medical technology industry.

The choice to describe the full-year outlook as a narrowing rather than an upgrade is the key tonal signal. Management added that price is slightly positive and, if FX holds at current levels, would be modestly favorable to both revenue and adjusted EPS. The results themselves deliver a strong recovery message, but the language of narrowing the guidance range may have sounded too conservative for the market to underwrite further upside.

Market Reaction and What to Watch Next

Despite the post-close release, after-hours trading saw a clear downside skew. With adjusted EPS and revenue both beating estimates, the share price weakness reflects the market weighing the full-year guidance range more heavily than the headline beat. With the top end of revenue growth lowered and the top end of EPS held flat, the read-through is that the Q2 beat did not fully flow through to the annual numbers. It is also possible that the cyberattack recovery narrative had already been priced in, and that good news triggered profit-taking on top.

Watch whether 3Q and 4Q organic revenue growth actually approaches the top end (9% range) of full-year guidance.

A rebound in the underperforming Vascular and Hip businesses will be pivotal for the durability of overall growth.

Monitor whether additional cyberattack-related costs or customer disruptions re-emerge and weigh on 2H margins.